Brief: Sosei Group Corp To Develop First-In-Class Treatments Targeting All Symptoms Of Schizophrenia With Boehringer Ingelheim
11/03/2024 06:33
Sosei Group Corp 4565.T :
* SOSEI GROUP CORP: TO DEVELOP FIRST-IN-CLASS TREATMENTS
TARGETING
ALL SYMPTOMS OF SCHIZOPHRENIA WITH BOEHRINGER INGELHEIM
Source text for Eikon: ID:nTSok86984
Further company coverage: 4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up